CAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Davide Ramoni und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Immunotherapy, Adoptive, Aging, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Ministero dell'Università e della Ricerca.
Abstract (Originalsprache)
Background
Short but impactful, the two‐decade story of gene editing allowed a significant breakthrough in the treatment of haematological malignancies. However, despite different generations of chimeric antigen receptor T (CAR T), such a successful therapy has not yet been replicated in solid tumours and non‐oncological diseases.
Methods
This narrative review discusses how CAR T therapy still faces challenges in overcoming the complexity of the solid tumour microenvironment and the concerns that its long‐term activity raises about potential unknown and unpredictable consequences in non‐oncological diseases.
Results
In the most recent studies, the senolytic potential of CAR T is becoming an exciting field of research. Still, experimental but promising results indeed indicate the clearance of senescent cells as an effective strategy to improve exercise capacity and metabolic dysfunction in physiological ageing, with long‐term therapeutic and preventive effects. However, an effective expansion of a CAR T population requires a lympho‐depleting chemotherapy prior to infusion. While this procedure sounds reasonable for rescue therapy of oncological diseases, it poses genotoxic risks that may not be justified for non‐malignant diseases. Those represent the leading gaps for applying CAR T therapy in non‐oncological diseases.
Conclusion
More is expected from current studies on the other classes of CAR cells now under investigation. Engineering NK cells and macrophages are candidates to improve cytotoxic and immunomodulating properties, potentially able to broaden application in solid tumours and non‐oncological diseases. Finally, engineering autologous T cells in old individuals may generate biologically deteriorated CAR T clones with impaired function and unpredictable effects on cytokine release.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Genoa, Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino Genoa, Italian Cardiovascular Network, Genoa, Italy.
ORCID-Profile: Fabrizio Montecucco, Federico Carbone
Förderung
- Ministero dell'Università e della Ricerca
Zitieren
APA
Ramoni, D., Montecucco, F., & Carbone, F. (2024). CAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14203
Vancouver
Ramoni D, Montecucco F, Carbone F. CAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14203
BibTeX
@article{Ramoni2024,
author = {Ramoni, Davide and Montecucco, Fabrizio and Carbone, Federico},
title = {CAR T therapy from haematological malignancies to aging‐related diseases: An ever‐expanding universe},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14203}
}
EUVIMED